Sinopsys is a medical device company that has developed the SLS stent technology for patients with Chronic Rhinosinusitis (CRS).
The technology has received a CE mark in Europe.
Headquartered in Boulder, Colorado, Sinopsys was founded to develop and test a stent technology that enables “top-down” access to the ethmoid sinus in a minimally invasive procedure.
To date, $20 million has been invested to develop the technology, to establish manufacturing and to collect clinical data to obtain CE mark approval in Europe. CE mark was granted in November 2015 and is up for renewal in November 2020
The Sinoposys board is comprised of health technology experts:
Richard Babb, President & CFO
Richard has over 30 years of diverse business, accounting and financial management experience, having been a Manager with Ernst & Young’s Entrepreneurial Services Group handling various venture capital clients, the Chief Financial Officer for Medical Science Partners, a Harvard-affiliated life science venture capital fund and as the NASD Chief Compliance Officer, for Apeiron Partners LLC.
Bob Di Scipio
Bob has over 30 years’ experience that spans biopharma, data analytics for the life science industry, corporate law and business development. Mr. Di Scipio currently serves as CEO and Chairman of Skyland Analytics, Inc., which provides Part 11-compliant cloud-based platforms for the management and analysis of process-product-patient data across the supply chain. Previously, Bob served as CEO of Aegis Analytical Corporation (acquired by Dassault Systèmes), VP of Business Development & Associate General Counsel at Martek Biosciences (NASDAQ:MATK), (acquired by DSM), and as General Counsel & VP Corporate Development of OmegaTech (acquired by Martek). He is a member of the bars of New York and Connecticut.
In 1998, Mark brought his research skills and business experience to Tango to focus on technology and Life Science investments. He is currently working with Taligen Therapeutics and BioResponse, two early stage biotechnology companies. Mark’s business experience came first in the brewing industry as founder, CEO and CFO of Tabernash Brewing Company, which was formed in 1993 and merged with Left Hand Brewing in 1998. He remains on the Board of Directors of the Left Hand and Tabernash Brewing Company. Mark holds a B.S. from Northwestern University and an MPhil from the University of Sussex (England) in Biomedical Engineering and a PhD in Pharmacology from the University of Lund, Sweden.
Richard Babb, President & CFO
CPA with extensive life science industry experience
CFO Medical Science Partners
US Management team
Regulatory and clinical affairs expert with 28+ years executive level experience
Experienced experts in product development and operations
Jürgen Raths, MD, Consultant, incoming CEO (Europe Based)
Former Sr. Executive with Eli Lily
Extensive experience as CEO in public and private healthcare companies
20 years of experience in creating European & global commercial pharmaceutical organizations
Incoming Management team (Europe)
With experienced experts in the areas of medical, regulatory, access & reimbursement, distribution & commercial who have worked together on successful commercial company set-ups in Europe and other parts of the world in the last 20 years.